Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Advances in Pathogenesis and Pathology Diagnosis of Gynecologic Cancers
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Pathogenesis and Pathology Diagnosis of Gynecologic Cancers

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 September 2026 | Viewed by 1565

Special Issue Editor

Prof. Dr. Wenxin Zheng

E-Mail Website
Guest Editor
1. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2. Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Interests: diagnostic challenges in gynecologic pathology; endometrial serous carcinogenesis; endometrial cancer pathogenesis; TCGA-endometrial cancer molecular classification; targeted therapy; immune therapy; uterine sarcoma; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent advances in molecular pathology and precision medicine have profoundly reshaped our understanding of gynecologic cancers. This Special Issue aims to highlight novel discoveries in the pathogenesis, classification, and diagnostic approaches of ovarian, endometrial, cervical, and related gynecologic malignancies. We welcome original research, comprehensive reviews, and translational studies that explore molecular mechanisms, diagnostic biomarkers, histopathologic correlations, and emerging technologies in tissue-based and liquid biopsy diagnostics. By integrating molecular and morphologic insights, this collection seeks to bridge the gap between laboratory research and clinical practice, ultimately improving patient management and outcomes in gynecologic oncology.

Prof. Dr. Wenxin Zheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecologic cancers
  • molecular pathology
  • tumor pathogenesis
  • diagnostic biomarkers
  • precision medicine
  • endometrial carcinoma
  • ovarian cancer
  • cervical cancer
  • histopathology
  • translational research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

24 pages, 3339 KB  
Article
Development of a Telehealth-Enabled Portable Optical Endomicroscopy System with Targeted Peptides: A Preclinical Feasibility Study for Cervical Cancer Detection
by Chanchai Thaijiam, Nitipon Navaitthiporn, Preeyarat Rithcharung, Nicholas Piyawattanametha, Shoji Komai, Supang Khondee and Wibool Piyawattanametha
Cancers 2026, 18(8), 1306; https://doi.org/10.3390/cancers18081306 - 20 Apr 2026
Viewed by 504
Abstract
Background/Objectives: We developed a telehealth-enabled fiber-bundle endomicroscopy platform and evaluated its preclinical feasibility for targeted fluorescence imaging in cervical cancer models. Methods: The platform integrates a portable fiber-bundle endomicroscopy (FBE) system, fluorescein isothiocyanate (FITC)-labeled candidate peptides, and a secure web-based telehealth platform for [...] Read more.
Background/Objectives: We developed a telehealth-enabled fiber-bundle endomicroscopy platform and evaluated its preclinical feasibility for targeted fluorescence imaging in cervical cancer models. Methods: The platform integrates a portable fiber-bundle endomicroscopy (FBE) system, fluorescein isothiocyanate (FITC)-labeled candidate peptides, and a secure web-based telehealth platform for remote consultation. The FBE probe achieved a field of view of 1,700 µm and a lateral resolution of 4 µm, enabling cellular-level fluorescence imaging in a compact, portable format. Four FITC-labeled peptides (SHS1*, SHS2*, FPP*, and CRL*) were evaluated in A549, SiHa, and CaSki cell lines. Ex vivo testing was performed on commercial cervical tissue-array samples. The telehealth platform was assessed for secure medical-image/video transmission and end-to-end latency in a simulated remote-consultation setting. Results: Among the tested probes, FPP*-FITC and CRL*-FITC showed higher fluorescence-positive fractions in the p16-overexpressing cervical cancer cell lines than in the A549 comparator line, with the strongest signals observed in CaSki cells. In ex vivo testing, CRL*-FITC generated higher fluorescence intensity in malignant cervical tissue-array samples than in non-malignant comparator tissues, with a reported 4.6- to 7.4-fold difference in mean signal intensity (p < 0.001). The telehealth platform supported the secure transmission of medical images and video and demonstrated an end-to-end latency of <500 ms in a simulated remote consultation setting. Conclusions: These results support the technical and preclinical feasibility of integrating targeted fluorescence imaging, portable fiber-bundle endomicroscopy, and telehealth into a single platform. This study should therefore be interpreted as a preclinical feasibility study evaluating optical, molecular, and telehealth integration, rather than as a clinically validated cervical cancer screening test. Full article
(This article belongs to the Special Issue Advances in Pathogenesis and Pathology Diagnosis of Gynecologic Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 3028 KB  
Review
ER-Negative Endometrial Cancers: An Evolving Diagnostic Category with Major Clinical Implications
by Rujia Fan, Xiaowei Wei, Jayanthi Lea, Huiting Zhu and Wenxin Zheng
Cancers 2026, 18(5), 773; https://doi.org/10.3390/cancers18050773 - 27 Feb 2026
Cited by 1 | Viewed by 744
Abstract
Estrogen receptor–negative (ER-negative) endometrial carcinomas represent an emerging and historically underrecognized diagnostic concept encompassing a biologically aggressive and heterogeneous subset of endometrial cancers. Although loss of ER expression is increasingly recognized as an adverse prognostic indicator, ER negativity alone is insufficient for precise [...] Read more.
Estrogen receptor–negative (ER-negative) endometrial carcinomas represent an emerging and historically underrecognized diagnostic concept encompassing a biologically aggressive and heterogeneous subset of endometrial cancers. Although loss of ER expression is increasingly recognized as an adverse prognostic indicator, ER negativity alone is insufficient for precise classification and must be interpreted within a histotype-specific and molecularly informed context. In this commentary, we review the evolving role of ER negativity in endometrial carcinoma through an integrated morphologic, immunophenotypic, and molecular framework, emphasizing both pathogenetic insights and practical diagnostic considerations. We highlight specific high-grade ER-negative tumor entities that merit particular diagnostic attention, including endometrial gastrointestinal-type adenocarcinoma, pilomatrix-like high-grade endometrial carcinoma, mesonephric-like adenocarcinoma, endometrial clear cell carcinoma, and ER-negative high-grade carcinomas not otherwise specified. These tumors exhibit distinct morphologic features and marked molecular heterogeneity that cannot be captured by hormone receptor status alone. Key diagnostic clues and common pitfalls are discussed, underscoring a practical workflow in which ER negativity serves as a diagnostic signal rather than a terminal category. Improved recognition and subclassification of ER-negative endometrial carcinomas are essential for accurate diagnosis, prognostic stratification, and optimized clinical management. Full article
(This article belongs to the Special Issue Advances in Pathogenesis and Pathology Diagnosis of Gynecologic Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop